This Pandemic Stock Has Just Begun to Push Higher


Keep an eye on Altimmmune Inc. (ALT).

The stock is pushing higher thanks to more positive data on its COVID candidate.

The company just published positive pre-clinical data for its new single-dose, intranasal COVID-19 vaccine candidate AdCOVID, adding the candidate “stimulates three key immune components: serum neutralizing antibody, T cell responses, and mucosal immunity in the respiratory tract.”

“AdCOVID is designed to offer significant advantages over other COVID-19 vaccine approaches, including intranasal administration, single-dose effectiveness, broad activation of the immune response, and the ability to ship and store the vaccine conveniently and inexpensively,” according to the company.